Overall survival and prognostic factors in lung cancer patients with brain metastases

2020 ◽  
Vol 27 (1) ◽  
pp. 159
Author(s):  
Fadime Demir ◽  
Ahmet Yanarates ◽  
Emine Budak
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Lung Cancer Patients

scholarly journals Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yanning Wang ◽  
Qianning Zhang ◽  
Chuansheng Chen ◽  
Yuxuan Hu ◽  
Liyun Miao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Hazard Ratios

BackgroundIn pivotal immunotherapy trials, the efficacy of immune checkpoint inhibitors as treatments for lung cancer patients with brain metastases remains controversial. The aim of this study was to assess the relative efficacy of immunotherapy versus standard systemic therapy in advanced lung cancer patients with and without brain metastases.MethodsSystematic searches of PubMed, Embase, Cochrane database, and conference proceedings up to Aug 6, 2020 without year and language restrictions. The main outcomes were the overall survival in patients with and without brain metastases measured by hazard ratios, and the difference in efficacy between patients with and without brain metastases was measured by ratio of hazard ratios.ResultsNine eligible randomized controlled trials involving 6241 patients (682 [11%] with brain metastases and 5559 [89%] without brain metastases) were included in the analysis. A survival benefit of immunotherapy was observed for both patients with brain metastases (HR, 0.75; 95%CI, 0.53-0.97; P = .026) and patients without brain metastases (HR, 0.75; 95%CI, 0.67-0.83; P <.001). However, patients without brain metastases benefit more from immunotherapy than patients with brain metastases (HR, 1.37; 95%CI, 1.15-1.63; P = .001). Additionally, subgroup analyses indicated that tumor type affect the efficacy of immunotherapy in patients with brain metastases (HR, 1.04 vs 1.54; interaction, P = .041).ConclusionsImmunotherapy can significantly improve overall survival for advanced lung cancer patients with asymptomatic brain metastases, especially in patients with non-small-cell lung cancer, but the magnitude of benefit is brain metastases dependent.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020206597.

The Relationship between Prognostic Factors and Overall Survival in Small Cell Lung Cancer Patients: a Single Centre Experience

2012 ◽  
Vol 13 (2) ◽  
pp. 60-64
Author(s):  
Bala Basak Oven Ustaalioglu ◽  
Ahmet Bilici ◽  
Mesut Seker ◽  
Taflan Salepci ◽  
Recep Ustaalioglu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Single Centre ◽  
Lung Cancer Patients ◽  
Single Centre Experience ◽  
The Relationship

P-726 Analysis of prognostic factors and outcomes in lung cancer patients who were initially diagnosed from manifestation of brain metastases

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S309
Author(s):  
H. Kawamura ◽  
Y. Nakayama ◽  
T. Nonaka ◽  
Y. Kitamoto ◽  
H. Ishikawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Lung Cancer Patients

scholarly journals Survival and Treatment of Lung Cancer in Taiwan between 2010 and 2016

2021 ◽  
Vol 10 (20) ◽  
pp. 4675
Author(s):  
Yen-Jung Chang ◽  
Jing-Yang Huang ◽  
Ching-Hsiung Lin ◽  
Bing-Yen Wang
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Randomized Clinical Trials ◽  
Treatment Strategies ◽  
Stage Iv ◽  
Clinical Staging ◽  
Lung Cancer Patients

Background: Lung cancer is the leading cause of cancer-related death, and its incidence is still growing in Taiwan. This study investigated the prognostic factors of overall survival between 2010 and 2016 in Taiwan. Methods: Data from 2010 to 2016 was collected from the Taiwan Cancer Registry (TCR). The characteristics and overall survival of 71,334 lung cancer patients were analyzed according to the tumor, node, metastasis (TNM) 7th staging system. Univariate and multivariate analysis were performed to identify the prognostic factors. Results: The five-year overall survival (n = 71,334) was 25.0%, and the median survival was 25.3 months. The five-year overall survival of patients receiving any kind of treatment (n = 65,436; 91.7%) and surgical resection (n = 20,131; 28.2%) was 27.09% and 69.93%, respectively. The clinical staging distribution was as follows: stage IA (9208, 12.9%), stage IB (4087, 5.7%), stage IIA (1702, 2.4%), stage IIB (1454, 2.0%), stage IIIA (5309, 7.4%), stage IIIB (6316, 8.9%), stage IV (41458, 58.1%). Age, sex, Charlson comorbidity index, cell type, clinical T, clinical N, clinical M, grading and treatment strategy are independent prognostic factors in the multivariate analysis. Conclusion: The outcome for lung cancer patients was still poor. The identification of prognostic factors could facilitate in choosing treatment strategies and designing further randomized clinical trials.

Sign in / Sign up

Export Citation Format

Share Document